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Abstract
Objectives Endometriosis presents with significant pain as
the most common symptom. Generic health measures can
allow comparisons across diseases or populations. However,
the Medical Outcomes Study Short Form 36 (SF-36) has not
been validated for this disease. The goal of this study was to
validate the SF-36 (version 2) for endometriosis.
Methods Using data from two clinical trials (N = 252
and 198) of treatment for endometriosis, a full complement
of psychometric analyses was performed. Additional
instruments included a pain visual analog scale (VAS); a
physician-completed questionnaire based on patient inter-
view (modified Biberoglu and Behrman—B&B); clinical
global impression of change (CGI-C); and patient satis-
faction with treatment.
Results Bodily pain (BP) and the Physical Component
Summary Score (PCS) were correlated with the pain VAS at
baseline and over time and the B&B at baseline and end of
study. In addition, those who had the greatest change in BP
and PCS also reported the greatest change on CGI-C and
patient satisfaction with treatment. Other subscales showed
smaller, but significant, correlations with change in the pain
VAS, CGI-C, and patient satisfaction with treatment.
Conclusions The SF-36—particularly BP and the PCS—
appears to be a valid and responsive measure for endo-
metriosis and its treatment.
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Background
Endometriosis is a common, chronic gynecological disease
among women of reproductive age. It is defined by the
growth of endometrium-like tissue outside the uterine
cavity, including the ovaries and other pelvic structures [1].
The condition is associated with a variety of symptoms,
with the main clinical symptoms such as dysmenorrhea
(pain on menstruation), dyspareunia (painful intercourse),
dyschezia (painful bowel movements), lower back pain,
and chronic pelvic pain [1–6]. It has been suggested that
chronic pelvic pain is the most important clinical factor of
endometriosis [7] and is commonly reported among women
with the condition. Moreover, it is a progressive disease
that worsens over time [8].
Among gynecological conditions, endometriosis is the
third leading cause of gynecological hospitalization in the
United States [9]. Exact prevalence is unknown as the
endometriosis can only be definitively diagnosed during
pelvic surgery, usually laparoscopy or laparotomy; there-
fore, most prevalence estimates are made on the basis of
surgical populations [10]. Estimates vary widely [11], but
the disease is generally estimated to occur in 5–10 % of
women in the general population [2, 10–15]. In women
with pelvic pain, the prevalence is even estimated to be 3 or
more times higher [2, 8, 16].
In addition to clinical symptoms, women with endo-
metriosis experience a range of non-clinical symptoms.
Depression and isolation are feelings often experienced.
Women with endometriosis report worse emotional well-
being than women with a primary diagnosis of depression,
hypertension, diabetes mellitus, heart disease, and arthritis
[17]. Problems with sex life and relationships are also
common [17, 18]. Women with endometriosis have
reported having less intercourse and more frequent inter-
ruption of intercourse due to pain [4]. Additionally, women
with endometriosis have difficulty in fulfilling work and
social commitments [19] and often report fatigue or lack of
energy [6, 20].
The existence of endometriosis-associated symptoms
has an adverse impact on physical, mental, and social well-
being and therefore a negative effect on health-related
quality of life (HRQOL) [19, 21–24]. This impact is
additionally magnified by the degree of severity of the
condition; more severe cases are associated with greater
reduction of HRQOL [18, 25].
Treatments aim to alleviate or significantly reduce pain,
thereby reducing the burden of the illness. For chronic
pain, the most important measures of treatment response
and reduction in illness burden involve patient-reported
outcomes (PROs) because the patient is the most important
judge of whether changes are important or meaningful [26,
27]. Clinical trials of endometriosis treatment have repor-
ted significant improvement in HRQOL assessed using
PRO measures following treatment [28–36]. Disease-spe-
cific PRO measures have been developed and as measures
of treatment efficacy, such as the Endometriosis Health
Profile—30 [37]. In addition, generic HRQOL PRO mea-
sures are also used in studies of endometriosis, with the
Medical Outcomes Study Short Form 36 (SF-36) being one
of the most common [22].
Although disease-specific instruments are more sensitive
to disease experiences than generic instruments [38], the
SF-36 has advantages of allowing comparisons across
diseases and between patients’ scores with those of the
general public. This information is useful in establishing a
thorough understanding of disease impact in relation to
other conditions and healthy individuals. The SF-36 has
been found to be responsive to change in health status in
women receiving treatment for endometriosis [39] but has
not been validated specifically for this condition.
The purpose of this study is to evaluate the validity of
the SF-36 in endometriosis, using data from two clinical
trials. A secondary objective is to examine the respon-
siveness and minimally important difference (MID) of the
SF-36 in patients with endometriosis. Use of the SF-36 in
endometriosis offers at least two advantages over disease-
specific measures for this condition or its symptoms. First,
as a generic health measure, it allows comparisons of
HRQOL of women with endometriosis with HRQOL
experiences of other diseases. Second, generic health
measures tend to be less sensitive to the disease experience
than disease-specific measures [38]. Thus, to the extent that
the SF-36 detects improvements resulting from treatment,
this would be stronger evidence of a treatment effect.
Methods
Data
Data came from two phase III studies of a treatment for
endometriosis-related symptoms. Study A is a 24-week,
multicenter, open-label, randomized, parallel-group, non-
inferiority study investigating the efficacy and safety of
daily oral administration of 2 mg dienogest versus intra-
muscular administration of 3.75 mg leuprorelin acetate
every 4 weeks for the treatment for symptomatic endo-
metriosis in 248 subjects with endometriosis [40]. Study B
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is a 12-week, double-blind, randomized, placebo-con-
trolled, parallel-group study designed to investigate the
efficacy and safety of daily oral administration of 2 mg
dienogest versus placebo for pelvic pain in 198 subjects
with endometriosis [41].
Measures
Data from three PRO measures and two clinician-com-
pleted measures were collected in both trials. Two of the
PROs and both clinician-completed measures were used to
validate the SF-36. The three PROs are described first
below followed by the descriptions of the clinician-com-
pleted instruments.
Medical Outcomes Study Short Form 36
The SF-36 is one of the most widely used generic measures
of health [2] and is commonly used in studies of endo-
metriosis and common gynecological conditions, including
endometriosis [22]. The SF-36 is a self-administered,
generic health status questionnaire that measures 8 health
concepts [42, 43]: ‘‘physical functioning (PF), role limita-
tions due to physical problems (RP), bodily pain (BP),
general health perception (GH), vitality (VT), social
functioning (SF), role limitations due to emotional prob-
lems (RE), and mental health (MH).’’ The typical factor
structure of the SF-36 hypothesizes that PF, RP, BP, and
GH are subscales of the physical component, while RE,
VT, MH, and SF are subscales of the mental component.
Scores can be calculated for each domain or by Physical
and Mental Component Summary Scores (PCS and MCS)
[43]. Scores are generally transformed to a range from 0 to
100 for the 8 subscales; the two components are normed
with z-scores of mean = 50.0 and SD = 10.0. For all
subscales and both components, a higher score indicates
better health status on each dimension. In this study, ver-
sion 2 of SF-36 was used.
The pelvic pain visual analog scale
As pain is the most dominant symptom of endometriosis,
patients indicated their endometriosis-associated pelvic
pain on a 100 mm visual analog scale (VAS). The ends of
the VAS were anchored with the descriptions (0) ‘‘absence
of pain’’ to (100) ‘‘unbearable pain.’’
Patient satisfaction with treatment
Only patients in Study B rated their satisfaction with treat-
ment (very much satisfied, much satisfied, minimally satis-
fied, neither satisfied nor dissatisfied, minimally dissatisfied,
much dissatisfied, very much dissatisfied). This was used to
assess the extent to which changes in the SF-36 subscales
and components show differences for varying levels of
treatment satisfaction.
The Biberoglu and Behrman severity profile
The Biberoglu and Behrman scale (B&B) [44] is a physi-
cian-completed questionnaire based on patient interview
referring to the previous 4 weeks. The B&B evaluates three
cardinal symptoms reported by endometriosis patients:
dysmenorrhea, dyspareunia, and pelvic discomfort/pain.
Each symptom has four possible intensities (0 = none,
1 = mild, 2 = moderate, and 3 = severe) based on the
patient’s self-assessment of pain and the gynecological
palpation by the attending physician. A summary score on
these three items (0 = none, 1–3 = mild, 4–6 = moderate,
and 7–9 = severe) is calculated. Physicians also rate 2
items on the same 0–3 scale that evaluate physical signs of
endometriosis: pelvic tenderness and induration, yielding a
summary score from 0 (none) to 5–6 (severe). A total
symptom severity score is calculated by summing the pain/
discomfort and physical signs scales.
Clinical global impressions of change
At the end-of-study visit, only in Study B, the investigator
assessed each patient’s improvement relative to symptoms
at baseline on the clinical global impressions of change
(CGI-C) [45], a 7-point scale: 1 = ‘‘Very much
improved,’’ 2 = ‘‘Much improved,’’ 3 = ‘‘Minimally
improved,’’ 4 = ‘‘No change,’’ 5 = ‘‘Minimally worse,’’
6 = ‘‘Much worse,’’ 7 = ‘‘Very much worse.’’ CGI-C was
administered at week 12 in the placebo-controlled study.
Assessment points
The SF-36 was completed at baseline and end of study
(week 24 for Study A; week 12 for Study B). The pelvic
pain VAS was completed at baseline and every 4 weeks in
both studies. The B&B was completed at baseline and
week 12 for both studies, and week 24 for Study A. Finally,
the CGI-C and patient satisfaction with treatment were
completed at week 12 for Study B only.
Analyses
As the factor structure of the SF-36 is generally well
established and because sample sizes for the two trials were
relatively small, analyses began with confirmatory factor
analyses (CFA). A confirmatory factor analysis of the SF-
36 was first conducted on Study A at baseline. Once a
satisfactory measurement model was obtained, confirma-
tory analyses were conducted using baseline data from
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Study B to see whether a comparable factor structure was
supported. The remaining psychometric analyses were
conducted on both trial datasets separately based on the
results of the factor structure from the CFA.
Confirmatory factor analysis
Confirmatory factor analyses using structural equation
modelling were conducted to confirm the measurement
model and fit of subscales within the hypothesized structure
of the SF-36. The analyses assessed the fit of an 8-factor and
2-summary-score solution as specified in the SF-36 standard
scoring manual [46]. Since confirmatory analyses require
relatively large sample sizes with sample size requirements
increasing as models become more complex [47], the
analyses were performed at the level of the subscales and
components, not the items, using total scores for each sub-
scale due to the relatively small sample sizes in each trial
(Study A = 252 and Study B = 198). Specifically, the
factors of physical functioning, role physical, bodily pain,
and general health were hypothesized as subscales of the
Physical Component Score and the factors of role emo-
tional, vitality, mental health, and social functioning were
hypothesized as subscales of the Mental Health Component
Score [46]. Overall model fit was assessed and factor
loadings were evaluated for acceptable magnitude (factor
loadings of 0.40 are conventionally considered acceptable).
Adequacy of fit was assessed using several fit indices:
Comparative Fit Index (CFI), standardized root mean residual
(SRMR), and root mean square error of approximation
(RMSEA) [47, 48]. In addition, modification indices were
examined for any anomalous results (e.g., correlated errors,
secondary loadings that were not explicitly modelled).
In the context of structural equation modelling, several fit
statistics provide information about the adequacy of the
model to explain the data [47]. In general, a model explains
the data well if the CFI, that is, the difference between the
hypothesized model and a null model, is 0.9 or better,
though there is some disagreement about 0.9 or 0.95 as the
lower threshold for the CFI [48]. The SRMR measures the
mean absolute difference between observed and model-
implied correlations; values of\0.1 are considered accept-
able [48]. As such, the SRMR is a measure of ‘‘badness of
fit’’ as a larger value represents a larger discrepancy between
the hypothesized model and the data. Finally, the RMSEA is
also a measure of the ‘‘badness of fit,’’ assessing the dis-
crepancy between the predicted and observed data per
degree of freedom; values\0.08 are considered acceptable
[49]. The 90 % confidence interval (CI) for the RMSEA
should be narrow, giving additional confidence in the esti-
mate. Once the model had been run and acceptable fit was
achieved using baseline data from Study A, the model was
confirmed using baseline data from Study B.
Internal consistency reliability
Once the factor structure of the SF-36 was confirmed,
internal consistency was assessed (Cronbach’s alpha;
standardized items are reported, though the results for
unstandardized items were identical to the third decimal
place) for each subscale first using baseline data from
Study A and then with baseline data from Study B.
Test–retest reliability was not performed due to the
relatively long lags between SF-36 assessments (Study A:
24 weeks; Study B 12 weeks).
The internal consistency reliability was assessed using
Cronbach’s formula for coefficient alpha:
a ¼ N  c
t þ N  1ð Þ  cð Þ
where N is the number of components (items or tests), t
equals the average variance, and c is the average of all
covariances between the components. In addition, the item-
rest correlation (i.e., the multiple correlation coefficient
‘‘R’’ for each item, having regressed each item on the
remaining items in the scale) was examined to see whether
any items are less correlated with the remaining items.
The standardized alpha was presented. This was based
on standardized scores (mean = 0 and standard devia-
tion = 1) for each of the items. There are no tests of sta-
tistical significance for alpha; the values are presented
descriptively on an interval level scale from 0 to 1.0, with
higher scores indicating a more reliable (precise) instru-
ment. The target Cronbach’s standardized alpha is at least
0.70, though patterns of item-to-item correlations and item-
to-total correlations are also important, as are the number
of items in the subscale. Moreover, an alpha that is too high
(e.g., approaching 1.0) can indicate a set of items that are
likely to be redundant, so this is not optimal.
Construct validity
Construct validity, the extent to which the instrument
measures what it is intended to measure, was evaluated in a
variety of ways. Specifically, SF-36 subscale and compo-
nent scores were correlated with the pelvic pain VAS item
(at baseline and end of study for both studies), B&B (pelvic
discomfort and pain and total score; at baseline and end of
study for both studies), and patient treatment satisfaction
rating (at week 12 in Study B). Spearman correlation
coefficients were used to evaluate these relationships.
Known groups/discriminant validity
Known groups/discriminant validity was assessed through
the ability of the SF-36 subscale and component scores to
discriminate between groups of patients according to the
Qual Life Res
123
levels of symptom severity, based on the B&B symptom
severity using analysis of variance (ANOVA) with Sche-
ffe’s post hoc comparisons. Mean differences between four
symptom severity groups at baseline were compared to
assess the relationship between SF-36 scores and symptom
severity item scores at baseline for both studies. Subjects
were stratified depending on their symptom severity item
scores. The groups were 0 (none), 1 (mild), 2 (moderate),
and 3 (severe).
A similar ANOVA strategy evaluated differences in
mean SF-36 subscale and component scores by VAS pain
severity groups. Quartiles of VAS pain severity groups
were created after examination of descriptive statistics, and
Scheffe’s post hoc comparisons of mean SF-36 scores
between quartiles were carried out.
Finally, for Study B, the mean change in SF-36 was
compared for different values of the CGI-C. These ANO-
VAs indicate whether those for whom the clinician rated as
‘‘Very much improved’’ had significantly higher mean
scores on the SF-36 subscales and components than those
with clinician ratings of change that were less improved.
Responsiveness and minimal important difference
To evaluate responsiveness of the SF-36 subscale and
component scores, correlations were computed between
changes in the SF-36 and changes in the pain VAS for
Study A, and between changes in the SF-36 with changes
in the pain VAS and the CGI-C for Study B.
Two methods—a priori and data-based—were used to
establish change thresholds for assessing the relationship
between minimal change in pain and the corresponding
change in the SF-36 bodily pain subscale and the PCS.
First, we used as a priori thresholds those suggested by
Farrar et al. [50] to anchor important changes in pain using
a 0–10 numerical rating scale. Farrar et al. [50] found that
changes of 1–2 points were considered small but important
to patients. Applying this finding to the 0–100 (‘‘absence of
pain’’ to ‘‘unbearable pain’’) VAS scale, those with a 10- to
29-point change toward the ‘‘0’’ end on the VAS scale were
considered as having a small but important change between
baseline and end of study, while VAS reductions of 30
points or more were considered moderate to large
improvements. Therefore, VAS improvements of 10–29
points represent a ‘‘responder,’’ and changes in the VAS of
less than 10 points in either direction (i.e., ±9 points) were
considered the stable group (‘‘non-responder’’).
Changes in VAS scores were grouped into 5 change
categories:
• Decrease of at least 30 mm (very much improved)
• Decrease between 10 and 29 mm (minimally improved)
• Decrease of 9 mm up to an increase of 9 mm (no
change)
• Increase between 10 and 29 mm (worse)
• Increase of at least 30 mm (very much worse).
The second approach used the distributions of change
based on the data in each study to establish change
thresholds rather than using a priori thresholds, that is,
based on the histograms of the change scores in the pain
VAS, and categories of ‘‘minimal change’’ and ‘‘no
change’’ were established. Interestingly, the category of
‘‘minimal change’’ was consistent with that noted above: a
change of 10–30 points, while the ‘‘no change’’ group had a
slightly larger range (-10–10).
A step-wise triangulation approach was used to establish
an MID for the SF-36 subscales. First, distribution-based
approaches were used to evaluate MID for Study A and then
for Study B. An anchor-based method using the CGI-C
measure from Study B was used to confirm an MID. Another
way of exploring the MID is to use receiver operating
characteristic (ROC) curves to look at sensitivity and spec-
ificity for different cut points when comparing patients who
improve versus those who show no change on the SF-36 over
the trial. The final cut point is one that strikes a balance
between sensitivity and specificity, and correctly identifies
the greatest proportion of patients with detectable improve-
ment without incorrectly identifying patients as having
improvement when in fact they did not. Two different ROC
curves were computed based on the pain VAS categories of
change noted above. In Farrar et al. [50], a priori category of
‘‘minimally improved’’ was compared with that of ‘‘no
change.’’ In a second analysis, the data-derived categories of
‘‘minimally improved’’ and ‘‘no change’’ were compared.
Results
Table 1 presents the baseline patient characteristics for
Studies A and B.
Confirmatory factor analysis
The model fit statistics of the CFA for both trials are pre-
sented in Table 2. The factor loadings for both trials and
correlations between the PCS and MCS are presented in
Fig. 1. The CFI was 0.92 and 0.91 for Studies A and B,
respectively, between the recommended thresholds of 0.9
and 0.95. The SRMR was below the threshold deemed
acceptable for both of the studies, further confirming the
hypothesized factor structure, that is, the mean differences
between the data-derived correlations and those implied by
the model were trivial. However, the reported RMSEA
values were outside of the acceptable range, especially for
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Study B where the 90 % CI was entirely above the rec-
ommended threshold of 0.08. It is possible, however, for
the RMSEA to be unacceptably high in simpler models,
such as those analyzed here [51]. In this case, both the CFI
and SRMR indicate acceptable fit and the RMSEA can be
ignored. Also, as shown in Fig. 1, all factor loadings were
above an acceptable threshold of 0.40.
Internal consistency reliability
The results of this part of the analysis are presented in
Table 3. Although the confirmatory factor analyses needed
to be performed with the subscales components, the
internal consistency reliabilities could be calculated for the
items within each subscale. In general, internal consistency
reliability of the subscales was acceptable with alpha above
the generally acceptable reliability value of 0.70. The two
scales that were closest to this threshold were general
health for Study A (alpha = 0.73) and role physical for
Study B (alpha = 0.75). The ‘‘alpha-if-deleted’’ changed
little for each of the eight subscales suggesting a high
degree of internal consistency for each subscale. The one
notable exception was item 5b (‘‘Accomplished less than
you would like’’) for role emotional. This was the case for
Table 1 Patient characteristics
at baseline
Study A (N = 252) Study B (N = 198)
Age mean (SD) 30. 8 (5.9) 31.4 (6.4)
Race/ethnicity n (%)
Caucasian 247 (98.0 %) 196 (99.0 %)
Hispanic 1 (0.4 %)
Asian 3 (1.2 %) 2 (1.0 %)
Other 1 (0.4 %)
Country of origin n (%)
Germany 166 (65.9 %) 60 (30.3 %)
Italy 20 (7.9 %) 19 (9.6 %)
Austria 10 (4.0 %)
Poland 36 (14.3 %)
Portugal 1 (0.4 %)
Spain 19 (7.5 %)
Ukraine 119 (60.1 %)
Baseline SF-36 n (%) at floor n (%) at ceiling n (%) at floor n (%) at ceiling
Physical functioning 0 54 (21.4) 0 21 (10.7)
Role physical 65 (25.9) 84 (33.5) 48 (24.4) 48 (24.4)
Bodily pain 14 (5.6) 11 (4.4) 2 (1.0) 3 (1.5)
General health perceptions 0 2 (0.8) 1 (0.5) 0
Vitality 1 (0.4) 0 2 (1.0) 0
Social functioning 2 (0.8) 61 (24.2) 1 (0.5) 22 (11.2)
Role emotional 52 (20.6) 125 (49.6) 44 (22.3) 83 (42.1)
Mental health 0 0 0 1 (0.5)
Pain VAS Mean SD Mean SD
Overall 54.4 26.6 56.9 17.9
Quartile 1 17.8 – 34.9 –
Quartile 2 46.5 – 48.3 –
Quartile 3 65.4 – 62.8 –
Quartile 4 86.6 – 80.6 –
B&B pelvic pain severity n % n %
None 2 0.8 1 0.5
Mild 69 27.4 34 18
Moderate 141 56 130 68.8
Severe 40 15.9 24 12.7
Qual Life Res
123
both trials. Standardized and unstandardized values were
calculated, but were negligibly different (at the third dec-
imal place).
Construct validity
Construct validity was assessed by correlations between the
SF-36 subscales and components and the pain VAS and
B&B pelvic discomfort and pain scores. Results of con-
struct validity analyses with the pain VAS for both trials
are presented in Table 4. In Study A, five SF-36 subscales
(PF, RP, BP, VT, and MH) and one component (PCS) were
statistically significantly correlated with the pain VAS at
baseline. At end of study, all subscales and both compo-
nents were statistically significantly related to the pain
VAS. For Study B, a similar, though slightly more com-
pelling, set of results emerged. Both SF-36 components and
all subscales, except GH, were statistically significantly
related to the pain VAS at baseline. At end of study, like
Study A, all subscales and both components were statisti-
cally significantly related to the pain VAS, though the
correlations for Study B were generally larger except for
MH. Of particular note is that the correlation of BP with
the pain VAS was moderate [52] for both studies at base-
line and end of study. The PCS was weakly correlated with
the pain VAS for Study A and Study B at baseline; at end
of study, it was moderately correlated in both studies
(r = -.41 and -.44). Other dimensions show only a weak
or sometimes very weak relationship.
Spearman correlations between SF-36 subscales and
components and the B&B pelvic discomfort and pain
exhibited a similar pattern of correlations at baseline and end
of study for both studies (results not shown). Correlations
tended to be larger at end of study than at baseline and for
Study B compared with Study A. Not surprisingly, BP had
the strongest correlation of the subscales with the B&B
pelvic discomfort and pain; the PCS had a slightly weaker
correlation with the B&B pelvic discomfort and pain.
Known groups/discriminant validity
Mean differences in SF-36 subscale and component scores
were compared by level of symptom severity on the B&B
symptom severity (none, mild, moderate, severe) using
ANOVA with Scheffe’s post hoc comparisons. Results of
these analyses are presented in Table 5 for baseline and
end of study for both studies (for details by B&B symptom
severity, see Appendix Table 9). For Study A at baseline,
with the exception of RE and the MCS, all SF-36 subscales
and the PCS were significantly associated with levels of
symptom severity. At end of study for Study A, both SF-36
components and all subscales, except GH, MH, and SF, and
the MCS were significantly associated with levels of
symptom severity when comparing pelvic pain severity
groups: patients with lower B&B symptom severity scores
(i.e., less severe) had better mean SF-36 subscale and
Table 2 Confirmatory factor analysis model fit statistics
Study A
(N = 252)
Study B
(N = 197)
Chi-square (df) 64.97 (19) 107.15
(19)
Comparative Fit Index 0.92 0.91
Root mean square error of approximation 0.1 0.15
90 % CI for root mean square error of
approximation
0.07–0.13 0.13–0.18
Standardized root mean residual 0.05 0.05
CI confidence interval, df degrees of freedom
PF
RP
BP
GH
PCS
RE
VT
MH
SF
MCS
0.59, 0.75
0.63, 0.80
0.53, 0.64
0.65, 0.75
0.81, 0.88
0.93, 0.82
0.74, 0.86
0.88, 0.86
0.64, 0.74
Note:  First coefficient: Study A; second coefficient: Study B
Study A, N = 252; Study B, N = 197
Fig. 1 Confirmatory factor analysis factor loadings (standardized)
Table 3 Reliabilities (Cronbach’s alpha) of SF-36 subscales and
components
Study A
(N = 252)
Study B
(N = 198)
Scale Alpha Scale Alpha
SF-36 subscales and items
Physical functioning 0.88 0.87
Role physical 0.83 0.75
Bodily pain 0.79 0.81
General health 0.73 0.81
Vitality 0.82 0.82
Social functioning 0.80 0.83
Role emotional 0.81 0.76
Mental health 0.87 0.85
SF-36 components and subscales
Physical health component 0.89 0.92
Mental health component 0.92 0.93
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component scores. The association was particularly strong
for the bodily pain SF-36 score and the PCS.
Similar, though somewhat less robust, results were seen
for Study B at baseline. Mean scores on PF, RP, BP, VT,
SF, and the PCS varied significantly by symptom severity
level of the B&B. At end of study, however, mean scores
for every SF-36 subscale and component varied signifi-
cantly by B&B severity level.
Responsiveness and minimally important difference
of the SF-36
Responsiveness of the SF-36 subscales and components
was evaluated by examining relationships between changes
in the SF-36 and changes in the pain VAS and, for Study B,
categories of CGI-C and patient satisfaction with treatment.
The scoring on the SF-36 change variables is such that a
lower or negative score indicates that the respondent got
worse (i.e., their end-of-study score was lower/worse than
their baseline score). Conversely, for the change in the pain
VAS score, a lower or negative score represents an
improvement (i.e., their end-of-study score was lower/
better than their baseline score). Table 6 presents correla-
tions between changes in SF-36 subscales and components
and changes in the pain VAS and summaries of ANOVA
F tests for comparisons of the mean changes in SF-36 with
categorical changes in the pain VAS (very much improved,
improved, no change, worse, very much worse). It was
hypothesized that those who reported improvement in pain
should also report improvements in their SF-36 scores,
especially the BP score.
Table 4 Pearson correlations between SF-36 subscale and compo-
nent scores and pain VAS, baseline and end of study
Study A Study B
N r N r
Baseline SF-36
Physical functioning 245 -.27 197 -.20
Role physical 244 -.24 197 -.28
Bodily pain 245 -.48 197 -.47
General health 242 -.10 197 -.05
Vitality 245 -.20 197 -.43
Social functioning 245 -.11 197 -.27
Role emotional 245 -.08 197 -.24
Mental health 245 -.14* 197 -.17*
Physical health
component score
241 -.38 197 -.29
Mental ealth
component score
241 -.06 197 -.24
EOS SF-36
Physical functioning 221 -.26 189 -.31
Role physical 220 -.32 189 -.32
Bodily pain 221 -.57 189 -.63
General health 218 -.21 188 -.28
Vitality 221 -.31 189 -.42
Social functioning 221 -.20 189 -.32
Role emotional 218 -.24 187 -.34
Mental health 221 -.32 189 -.28
Physical health
component score
214 -.41 186 -.44
Mental health
component score
214 -.23 186 -.31
* P B 0.05;  P B 0.01;  P B 0.001
Table 5 Discriminant validity
of the SF-36 scores: ANOVA by
Biberoglu & Behrman symptom
severity level at baseline and
end of study
* P B 0.05;  P B 0.01;
 P B 0.001
Baseline End of study
B&B severity
—Study A
B&B severity
—Study B
B&B severity
—Study A
B&B severity
—Study B
F F F F
Physical functioning 4.37 2.98* 6.58 7.27
Role physical 7.25 3.11* 4.83 7.40
Bodily pain 14.93 15.77 27.98 27.30
General health 5.78 2.24 1.15 15.30
Vitality 5.24 3.84* 4.36* 11.19
Social functioning 4.19 2.70* 0.83 7.11
Role emotional 1.21 0.65 3.47* 3.59*
Mental health 2.63* 2.34 2.81 7.59
Physical health component 11.53 7.42 13.57 18.21
Mental health component 1.59 1.12 1.52 5.31
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For both trials, correlations between changes in SF-36
and changes in the pain VAS indicated that decrements in
pain VAS scores (i.e., lessening pain) were correlated with
improvements in SF-36 subscale and component scores
(i.e., greater SF-36 scores). This was particularly notable
for the BP subscale and the PCS. These results are reflected
in the negative correlations seen in the first two columns of
Table 6.
For Study A, those whose mean pain VAS scores
improved from baseline to end of study had significantly
higher mean improvement in the PCS and all SF-36 sub-
scales, except for GH, MH, and SF. Bodily pain and PCS
exhibited a particularly strong and statistically significant
relationship. For Study B, those whose mean pain VAS
scores improved from baseline to end of study had sig-
nificantly higher mean improvement in the PCS and all SF-
36 subscales, except for MH and MCS.
Improvement based on the CGI-C and patient satisfac-
tion with treatment in Study B was associated with
improvement in the SF-36 for several subscales and the
PCS. Specifically for the CGI-C, the SF-36 subscales of
BP, GH, RE, and VT all had significantly higher means for
patients whose clinicians indicated that they had greater
improvement in their symptoms since baseline. For patient
satisfaction with treatment, mean scores for RP, BP, GH,
and PCS were greater for those who had greater satisfac-
tion with treatment for their condition.
Minimally Important Differences analyses
Study A
Table 7 presents the results of the MID analyses. The
results suggest some highly varied MIDs for the SF-36
subscales and components, ranging from about 4 to over 20
for Study A and from under 4 to 20 for Study B. Given the
central role that pain plays in endometriosis, the BP sub-
scale and the PCS (of which BP is a component) will be the
focus of detailed results. As seen in Table 7, half of the
standard deviation of the change in BP is 15. This is
slightly larger than the standard error of mean (SEM)
(10.4). The SEM describes the error associated with the
measure. Wyrwich has shown that this approach closely
mirrors results using an approach based on patient global
assessment of change [2, 38]. Moreover, these are associ-
ated with a substantial effect size (ES) of 1.43, suggesting
that a change of this size is meaningful.
Receiver operating characteristic curves were calculated
to compare those who showed minimal change on the pain
VAS versus those who did not change, using the cut points
adapted from Farrar et al. [50] (see Table 8). The results of
the ROC curves (not presented) suggest that a score
between 16 and 21 represents a balance between sensitivity
and specificity, correctly classifying 73 % of cases. The
second method of setting thresholds of change (using dis-
tributions of change based on the data rather than the a
priori thresholds suggested by Farrar et al. [50]) suggested
that a score of 21 represents a balance between sensitivity
Table 6 ANOVAs assessing
mean change in SF-36 by mean
change in pelvic pain VAS from
baseline to end of study and
correlations between changes in
SF-36 scores and changes in
pain VAS from baseline to end
of study
r Denotes a correlation
coefficient
 P B 0.05;  P B 0.01;
§ P B 0.001
a Very much improved (n:
Study A = 136; Study B = 60);
improved (n: Study A = 46;
Study B = 78), no change (n:
Study A = 25; Study B = 45),
worse (n: Study A = 8; Study
B = 3), very much worse (n:
Study A = 1; Study B = 1)
Correlation of
change in SF-
36 with change
in pain VAS
Change in pain
VASa
Change in pain
VASa
CGI-C Patient
satisfaction
with treatment
Study
A
Study
B
Study A Study B Study B
r r F-statistic F-statistic F-
statistic
F-statistic
D Physical functioning -.26§ -.19 4.59§ 2.43 1.75 0.65
D Role physical -.24§ -.26§ 5.06§ 3.26 2.07 4.06
D Bodily pain -.43§ -.62§ 10.46§ 21.52§ 18.40§ 8.52§
D General health -.09 -.21 2.02 3.14 2.41 2.36
D Vitality -.15 -.30§ 3.03 4.23 2.84 2.09
D Social functioning -.03 -.23 0.81 2.95 1.610 1.67
D Role emotional -.13 -.24§ 2.83 3.14 2.94 1.84
D Mental health -.07 -.14 1.93 0.73 1.07 0.71
D Physical health
component
-.37§ -.45§ 8.57§ 10.35§ 6.79§ 6.77§
D Mental health
component
-.02 -.17 1.60 1.40 1.13 1.44
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and specificity, correctly classifying 70 % of cases
(detailed results not presented).
For the PCS, half of the standard deviation of change is
4.6 which is also the value for the SEM (see Table 8). This
corresponds to a large ES of 0.97. The score from the ROC
curves (using the Farrar et al. [50] method) that balances
sensitivity and specificity is 3.7 and correctly classifies
61 % of cases. The score from the ROC curves (using the
alternative method for establishing change categories) that
balances sensitivity and specificity is 3.8 and correctly
classifies 61 % of cases (results not presented).
Study B
For BP, we see that half of the standard deviation of the
change is 11 (see Table 8). This is slightly larger than the
SEM (7.2) but these correspond to an ES of 0.99. The
results of the ROC curves based on the pre-defined cut
points suggested by Farrar et al. [50] suggest that a score of
10 represents a balance between sensitivity and specificity,
correctly classifying 63 % of cases (results not presented).
Using pain VAS cut points based on the data in the study
(alternative method), a score of 9 represents a balance
Table 7 Results of minimally important difference
SF-36 score N Baseline
mean
End of study
mean
End of study—
baseline
SD,
baseline
SD of
change
Half SD of
change
a SEMa SRMb ESc
Study A
Physical
functioning
234 81.8 90.7 8.9 18.4 18.9 9.5 0.88 6.37 0.47 0.49
Role physical 232 54.2 81.1 26.9 40.5 45.2 22.6 0.83 16.70 0.60 0.67
Bodily pain 234 42.4 75.8 33.4 23.3 30.1 15.1 0.80 10.44 1.11 1.43
General health
perceptions
228 59.7 62.9 3.2 21.3 19.9 9.9 0.73 11.05 0.16 0.15
Vitality 234 49.1 57.2 8.2 19.3 20.1 10.1 0.83 7.97 0.41 0.42
Social functioning 234 70.2 79.3 9.1 23.5 26.0 13.0 0.80 10.52 0.35 0.39
Role emotional 231 64.6 77.5 12.8 40.4 46.1 23.1 0.82 17.12 0.28 0.32
Mental health 234 60.8 66.2 5.4 19.7 18.3 9.1 0.87 7.12 0.29 0.27
Physical health
component
223 43.2 51.4 8.2 8.5 9.3 4.6 0.70 4.64 0.88 0.97
Mental health
component
223 43.9 45.7 1.7 11.6 11.6 5.8 0.85 4.50 0.15 0.15
Study B
Physical
functioning
190 76.9 85.2 8.3 18.8 14.6 7.3 0.87 6.79 0.56 0.44
Role physical 190 51.2 70.4 19.2 37.8 36.7 18.4 0.75 18.91 0.52 0.51
Bodily pain 190 42.8 59.1 16.3 16.5 22.4 11.2 0.81 7.19 0.73 0.99
General health
perceptions
189 46.1 53.3 7.2 20.7 15.3 7.6 0.81 9.02 0.47 0.35
Vitality 190 49.5 55.3 5.8 19.1 15.5 7.8 0.82 8.10 0.37 0.30
Social functioning 190 64.4 73.2 8.8 23.0 19.9 9.9 0.83 9.49 0.44 0.38
Role emotional 188 59.2 73.4 14.2 40.2 40.5 20.2 0.76 19.72 0.35 0.35
Mental health 190 58.0 62.6 4.5 18.5 14.8 7.4 0.85 7.15 0.31 0.25
Physical health
component
187 41.1 46.3 5.3 7.4 6.9 3.5 0.82 3.14 0.76 0.71
Mental health
component
187 42.3 44.8 2.5 10.9 9.5 4.7 0.89 3.61 0.26 0.23
a = Cronbach’s coefficient of internal consistency reliability; SEM = standard error of measurement; SRM = standardized response mean;
ES = effect size
a SEM = SD H(1 - a)
b SRM = change score/SD of the change score
c ES = change score/SD at baseline
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between sensitivity and specificity, correctly classifying
63 % of cases (results not tabled).
For the PCS, half of the standard deviation of change is
3.5 while the value for the SEM is 3.1. This corresponds to
an effect size of 0.71. The score from the ROC curves
(Farrar et al. [50] method) that balances sensitivity and
specificity is 2.9 and correctly classifies 61 % of cases
(results not presented). ROC curves using the alternative
method for establishing thresholds of change suggest that a
score of 3 balances sensitivity and specificity and correctly
classifies 61 % of cases (results not tabled).
Using the anchor-based approach (CGI-C) for Study B,
comparing ‘‘minimally improved’’ with ‘‘no change’’ in
their condition, this corresponded to a BP change of 10.7
and a mean improvement in PCS of 4 (see Table 8).
Summary of MID results
A summary of the results from the MID analyses is pre-
sented in Table 8. The results suggest some triangulation
on an MID for both the BP subscale and the PCS, although
there was more variability in a possible MID for bodily
pain for Study A. For example, a possible MID ranged
from 10.4 (SEM) to 21 (ROC curves). A score of around
15–16 seems to fall in the middle of this range for a
minimally important change from a patient’s perspective
for Study A. For Study B, there was much more consis-
tency in the possible MID values for bodily pain. A score
of 11 is a likely value for a minimally important change
from the patients’ perspective, based on the half standard
deviation of the change, the SEM. The ROC curves
suggest a score of 9–10, which is close to the value
suggested by the other approaches. Thus, based on these
two studies, it appears that a change in the bodily pain
subscale between 11 and 16 represents a meaningful
change to patients.
Results for the PCS are a little tighter and generally
more consistent across the two trials than for the bodily
pain subscale. A possible MID ranged from 2.9–3.0 (ROC
curves) to 4.6 (half standard deviation of change and
SEM). The ROC curves for Study A yielded a value of
3.7–3.8; half standard deviation of change for Study B
resulted in a value of 3.5; the anchor-based results using
the CGI-C resulted in a value of 4.1. Therefore, it is likely
that a change in the PCS in the range of 3.7–3.8 is a
meaningful change to patients.
Discussion
The purpose of this study was to establish the psychometric
validity and responsiveness of the SF-36 in endometriosis.
A secondary goal was to determine the MID for SF-36
subscales and components. Establishing the psychometric
properties and an initial MID for SF-36 is an important step
in evaluating the effect of endometriosis on women’s
HRQOL and the efficacy of treatments for this condition.
That the results from two different trials—an active com-
parator trial and a placebo-controlled trial—were very
Table 8 Summary of results
from minimally important
difference analyses
CGI-C = clinical global
impression of change;
ROC = receiver operating
characteristic
a n = 121
b n = 69
c n = 109
Bodily pain subscale
Study A (n = 234) Study B (n = 190)
Half of the standard deviation of change 15 11
Standard error of measurement 10.4 7.2
Effect size of change 1.43 0.99
ROC curves (Farrar et al. method) 16–21a 10b
ROC curves (alternate method) 21 9
Anchor-based—CGI-C – 10.7c
Physical Component Summary Score
Study A (n = 232) Study B (n = 187)
Half of the standard deviation of change 4.6 3.5
Standard error of measurement 4.6 3.1
Effect size of change 0.97 0.71
ROC curves (Farrar et al. method) 3.7a 2.9b
ROC curves (alternate method) 3.8 3
Anchor-based—CGI-C – 4.1c
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similar lends confidence in the results and the robustness of
conclusions.
The overall results of the psychometric analyses provide
evidence of the validity of the SF-36 for this patient pop-
ulation. The factor structure, construct validity, internal
consistency reliability, known groups/discriminant validity,
and responsiveness indicate that the SF-36, especially the
BP subscale and the PCS, is a valid, reliable, and respon-
sive instrument for measuring HRQOL for women with
endometriosis.
To establish the psychometrics of the SF-36, two mea-
sures that are generally accepted as appropriate indicators
of HRQOL for women with endometriosis—pain VAS and
the B&B—were used as comparator measures. Although
correlations between the SF-36 and the pain VAS were
somewhat mixed (some weak but significant while others
were moderate), it performed in expected ways. Further,
the results of the ANOVAs with the B&B were consistent
with those of the correlations with the pain VAS. Women
who reported more pain at baseline on the pain VAS and
whose B&B scores were more severe were significantly
more likely to have poorer scores on most of the SF-36
subscales, especially the BP and PCS.
Results were also favorable for the SF-36 as a measure
that is responsive to change: Patients whose pain VAS
scores improved also had improved mean SF-36 scores.
Further, those whose pain VAS scores improved the most
had the largest improvements in SF-36 scores.
Minimally important difference estimates from this
study suggest that, based on the effect size, the BP subscale
and the PCS are the two dimensions of the SF-36 that show
a strong effect, supporting their ability to detect treatment
effects or differences. MID estimates for the bodily pain
subscale are in line with those of the developer [53]. For
the PCS, MID estimates were close to those that have been
published elsewhere, although these were in different
indications [54, 55].
The consistency of results across two different trials—
active comparator and placebo-controlled—demonstrated
that the SF-36 has value in describing the experience of
women with endometriosis. This instrument appears to be
sensitive to changes in pain or discomfort and differences
in effects of treatment. Not surprisingly, given that pain is
the most prevalent symptom in endometriosis, BP and PCS,
which includes the BP subscale, were especially sensitive
to differences in experience and changes in condition.
Recently, using some of the same clinical trial data,
Gerlinger and colleagues [56] reported that the minimal
important difference (MID) of the pain VAS was 10 mm.
This represents the lower threshold used in the present
study based on Farrar et al. [50] Thus, the MID values for
the SF-36 reported here based on the Farrar et al. approach
are likely to be similar to those if the Gerlinger et al. MID
value was used.
No single method of establishing an MID is ideal or
accepted and each one makes certain assumptions about
change [57]. Consequently, researchers use multiple
methods and triangulate on a value that is consistent or
within a consistent range across the methods used. That
was the case in the present study. As seen in Tables 7 and
8, there was general consistency in MID values across the
two studies. Thus, while some may take issue with the use
of the pain VAS as an anchor and the particular catego-
rizing of the pain VAS, the results from using that anchor
correspond reasonably well with the MID results from the
other methods used, especially for Study B.
Although there is some debate about the factor structure
of the SF-36, there is general consistency in the second-
order factor structure (i.e., the subscales that load under the
PCS and MCS; [58–60]). The results of the present study
are in line with these findings.
That the SF-36, a generic measure of health, appears to
be a valid measure for endometriosis and its treatment is
advantageous in at least two ways. First, comparisons can
be made with other diseases and with general populations,
particularly since the PCS has been normed for many
populations and diseases. Second, as a generic measure of
health, it is likely to be less sensitive to condition-specific
changes. The present findings indicate that the SF-36 can
detect differences in patients’ conditions and changes in
their conditions. Therefore, this suggests that changes in
the SF-36 in the context of a clinical trial on the order of
the MID reported here are likely to be meaningful and real.
This lends confidence in the SF-36 being a valid and
responsive measure for endometriosis, and provides evi-
dence that BP and the PCS are especially informative when
evaluating the HRQOL impact on patients with diagnosed
or suspected endometriosis.
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See Table 9.
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Table 9 Mean SF-36 Domain
and Component Scores by
pelvic pain symptom severity,
baseline, and follow-up
Symptom severity
groups
Study A Study B
Baseline Follow-up Baseline Follow-up
SF-36 ScoreMean
(SD) [n]
SF-36 ScoreMean
(SD) [n]
SF-36 ScoreMean
(SD) [n]
SF-36 ScoreMean
(SD) [n]
Physical
functioning
* * * *
None 91.3 (10.1) [23] 92.8 (13.2) [148] 97.5 (3.5) [2] 93.7 (13.1) [27]
Mild 82.6 (15.6) [84] 87.7 (18.0) [71] 82.5 (14.4) [43] 87.4 (11.9) [99]
Moderate 80.8 (20.0) [113] 84.9 (13.1) [15] 76.4 (18.7) [121] 79.2 (18.4) [59]
Severe 75.6 (22.0) [32] 100.0 (–) [1] 70.6 (22.5) [31] 66.7 (12.1) [6]
Role physical * * * *
None 72.8 (38.4) [23] 85.4 (27.4) [147] 75.0 (0.0) [2] 92.6 (13.1) [27]
Mild 59.8 (39.4) [84] 76.8 (35.4) [71] 64.5 (32.4) [43] 74.3 (30.9) [99]
Moderate 51.6 (39.3) [112] 61.7 (38.8) [15] 48.5 (39.3) [121] 57.6 (37.5) [59]
Severe 32.8 (39.4) [32] 100.0 (–) [1] 43.5 (35.3) [31] 33.3 (30.3) [6]
Bodily pain * *
None 45.7 (30.2) [23] 82.2 (22.6) [147] 71.0 (41.0) [2] 79.6 (21.3) [27]
Mild 51.5 (23.2) [84] 69.6 (19.6) [71] 53.0 (15.2) [43] 62.7 (17.4) [99]
Moderate 38.7 (20.3) [113] 43.1 (24.2) [15] 42.5 (14.9) [121] 46.6 (17.1) [59]
Severe 25.2 (17.6) [32] 42.0 (–) [1] 29.1 (13.6) [31] 30.0 (9.4) [6]
General health * *
None 66.7 (18.2) [23] 64.8 (22.6) [146] 67.0 (7.1) [2] 73.4 (19.1) [26]
Mild 62.5 (20.0) [82] 59.3 (20.4) [70] 48.9 (19.8) [43] 54.7 (16.8) [99]
Moderate 58.5 (20.9) [112] 56.9 (19.7) [15] 45.2 (19.5) [121] 44.1 (17.3) [59]
Severe 47.7 (23.7) [32] 72.0 (–) [1] 44.8 (25.7) [31] 34.0 (17.8) [6]
Vitality * * * *
None 55.9 (19.1) [23] 60.2 (19.5) [148] 67.5 (10.6) [2] 65.0 (17.3) [27]
Mild 51.1 (16.4) [84] 53.2 (19.9) [71] 54.4 (14.3) [43] 58.5 (15.3) [99]
Moderate 47.7 (19.9) [113] 44.0 (20.9) [15] 49.6 (19.0) [121] 47.3 (18.2) [59]
Severe 39.8 (21.5) [32] 60.0 (–) [1] 39.8 (22.2) [31] 35.0 (24.5) [6]
Social functioning * *
None 70.7 (21.2) [23] 80.9 (22.4) [148] 81.3 (8.8) [2] 87.0 (15.7) [27]
Mild 74.4 (22.3) [84] 76.4 (22.0) [71] 71.5 (21.9) [43] 76.1 (19.9) [99]
Moderate 69.5 (25.0) [113] 75.8 (26.1) [15] 63.2 (21.7) [121] 65.3 (20.4) [59]
Severe 56.6 (26.6) [32] 100.0 (–) [1] 56.9 (26.6) [31] 41.7 (18.8) [6]
Role emotional *
None 71.0 (35.3) [23] 81.8 (33.1) [145] 33.3 (47.1) [2] 91.4 (23.7) [27]
Mild 63.9 (42.4) [84] 70.0 (39.9) [71] 69.8 (37.7) [43] 75.9 (31.1) [97]
Moderate 65.8 (40.6) [113] 71.1 (39.6) [15] 56.7 (39.8) [121] 65.5 (38.6) [59]
Severe 52.1 (38.7) [32] 100.0 (–) [1] 54.8 (45.2) [31] 27.8 (44.3) [6]
Mental health * * *
None 51.7 (7.2) [23] 53.4 (7.0) [148] 62.0 (19.8) [2] 74.1 (18.0) [27]
Mild 51.1 (6.5) [84] 50.7 (6.4) [71] 63.0 (18.0) [43] 63.5 (14.5) [99]
Moderate 51.2 (6.8) [113] 49.9 (5.8) [15] 57.6 (17.8) [121] 58.2 (16.6) [59]
Severe 50.0 (8.0) [32] 64.0 (–) [1] 51.0 (20.4) [31] 41.3 (15.9) [6]
Physical health
component
* * * *
None 49.1 (6.8) [23] 55.0 (6.9) [142] 55.0 (12.3) [2] 53.0 (6.9) [26]
Mild 46.7 (8.8) [82] 51.2 (8.8) [70] 44.1 (7.0) [43] 47.7 (6.1) [97]
Moderate 43.2 (8.6) [111] 45.1 (8.0) [15] 40.8 (7.2) [121] 42.0 (7.0) [59]
Severe 38.1 (9.8) [32] 50.5 (–) [1] 38.1 (7.6) [31] 37.9 (5.8) [6]
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